Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Opens in a new tab or window SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The recent success of drug therapies such as semaglutide and tirzepatide has fueled obesity research. In a phase 2 trial that enrolled patients with type 2 diabetes (ClinicalTrials.gov Identifier: ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Scientists from Yale and other institutions have discovered that tirzepatide, a drug approved to treat type 2 diabetes, may also be highly effective for weight loss in people with obesity. This ...

This implies monthly maintenance doses, which would give it a big leg up on tirzepatide and semaglutide, which require weekly ...

The average 15.4%-22.9% weight losses across the tirzepatide doses achieved initially in the trial were maintained throughout ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the weight-loss effects of the two blockbuster slimming jabs ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).